Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer

CORCEPT THERAPEUTICS INC

NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.
Improved progression-free and overall survival vs nab-paclitaxel monotherapy; no biomarker selection needed.
Relacorilant well-tolerated; adverse events similar to monotherapy, no increased safety burden.
CEO notes this is Corcept's second NDA before FDA; relacorilant also under review for hypercortisolism.
Company preparing launch once approved; oncology and endocrinology units in place.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.